EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Detection of High‐Risk Paraneoplastic Antibodies against TRIM9 and TRIM67 Proteins

Christopher M Bartley iD, Thomas T Ngo, Le Duy Do, Anastasia Zekeridou iD, Ravi Dandekar, Sergio Muñiz-Castrillo iD, Bonny D Alvarenga, Kelsey C Zorn, Asritha Tubati, Anne-Laurie Pinto, Weston D Browne, Patrick W Hullett und 15 weitere

Annals of Neurology · 2023-12 · 94 (6) · 1086-1101

DOI: 10.1002/ana.26776 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Neurology, online erschienen am 19.09.2023. Verfasst von Christopher M Bartley und 26 weiteren Autor:innen. Beteiligte Einrichtung: Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Nerve Tissue Proteins, Paraneoplastic Cerebellar Degeneration. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIMH NIH HHS, NIA NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Co‐occurring anti‐tripartite motif‐containing protein 9 and 67 autoantibodies (TRIM9/67‐IgG) have been reported in only a very few cases of paraneoplastic cerebellar syndrome. The value of these biomarkers and the most sensitive methods of TRIM9/67‐IgG detection are not known.

Methods

We performed a retrospective, multicenter study to evaluate the cerebrospinal fluid and serum of candidate TRIM9/67‐IgG cases by tissue‐based immunofluorescence, peptide phage display immunoprecipitation sequencing, overexpression cell‐based assay (CBA), and immunoblot. Cases in which TRIM9/67‐IgG was detected by at least 2 assays were considered TRIM9/67‐IgG positive.

Results

Among these cases (n = 13), CBA was the most sensitive (100%) and revealed that all cases had TRIM9 and TRIM67 autoantibodies. Of TRIM9/67‐IgG cases with available clinical history, a subacute cerebellar syndrome was the most common presentation (n = 7/10), followed by encephalitis (n = 3/10). Of these 10 patients, 70% had comorbid cancer (7/10), 85% of whom (n = 6/7) had confirmed metastatic disease. All evaluable cancer biopsies expressed TRIM9 protein (n = 5/5), whose expression was elevated in the cancerous regions of the tissue in 4 of 5 cases.

Interpretation

TRIM9/67‐IgG is a rare but likely high‐risk paraneoplastic biomarker for which CBA appears to be the most sensitive diagnostic assay. ANN NEUROL 2023;94:1086–1101

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nerve Tissue ProteinsParaneoplastic Cerebellar DegenerationHumansRetrospective StudiesBiomarkersAutoantibodiesImmunoglobulin G

Substanzen

Nerve Tissue ProteinsBiomarkersAutoantibodiesImmunoglobulin G

Autor:innen und Institutionen

  • Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
  • Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA, USA.
  • Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
  • French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon and SynatAc Team, Institut Mechanisms in Integrated Life Sciences, L'Institut national de la santé et…
  • Department of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Christopher M Bartley, Anastasia Zekeridou, Sergio Muñiz-Castrillo, Sean J Pittock, Jérôme Honnorat, Michael R Wilson

Förderung

  • NIMH NIH HHS
  • NIA NIH HHS
  • NIH HHS
  • NCI NIH HHS
  • NINDS NIH HHS
  • NIGMS NIH HHS
  • National Institute of Mental Health
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Bartley, C. M., Ngo, T. T., Do, L. D., Zekeridou, A., Dandekar, R., Muñiz-Castrillo, S., Alvarenga, B. D., Zorn, K. C., Tubati, A., Pinto, A. L., Browne, W. D., Hullett, P. W., Terrelonge, M., Schubert, R. D., Piquet, A. L., Yang, B., Montalvo, M., Kung, A. F., Mann, S. A., …, & Wilson, M. R. (2023). Detection of High‐Risk Paraneoplastic Antibodies against TRIM9 and TRIM67 Proteins. Annals of Neurology, 94(6), 1086-1101. https://doi.org/10.1002/ana.26776

Vancouver

Bartley CM, Ngo TT, Do LD, Zekeridou A, Dandekar R, Muñiz-Castrillo S, et al. Detection of High‐Risk Paraneoplastic Antibodies against TRIM9 and TRIM67 Proteins. Annals of Neurology. 2023;94(6):1086-1101. doi:10.1002/ana.26776

BibTeX
@article{Bartley2023,
  author = {Bartley, Christopher M and Ngo, Thomas T and Do, Le Duy and Zekeridou, Anastasia and Dandekar, Ravi and Muñiz-Castrillo, Sergio and Alvarenga, Bonny D and Zorn, Kelsey C and Tubati, Asritha and Pinto, Anne-Laurie and Browne, Weston D and Hullett, Patrick W and Terrelonge, Mark and Schubert, Ryan D and Piquet, Amanda L and Yang, Binxia and Montalvo, Mayra and Kung, Andrew F and Mann, Sabrina A and Shah, Maulik P and Geschwind, Michael D and Gelfand, Jeffrey M and DeRisi, Joseph L and Pittock, Sean J and Honnorat, Jérôme and Pleasure, Samuel J and Wilson, Michael R},
  title = {Detection of High‐Risk Paraneoplastic Antibodies against TRIM9 and TRIM67 Proteins},
  journal = {Annals of Neurology},
  year = {2023},
  volume = {94},
  number = {6},
  pages = {1086--1101},
  doi = {10.1002/ana.26776}
}
Kostenlos starten →